{"id":56089,"date":"2023-04-21T15:03:31","date_gmt":"2023-04-21T13:03:31","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/guardant-health-announces-new-data-to-be-presented-at-2023-digestive-disease-week-showcasing-the-potential-of-its-blood-based-technology-to-detect-colorectal-cancer\/"},"modified":"2023-04-21T15:03:31","modified_gmt":"2023-04-21T13:03:31","slug":"guardant-health-announces-new-data-to-be-presented-at-2023-digestive-disease-week-showcasing-the-potential-of-its-blood-based-technology-to-detect-colorectal-cancer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/guardant-health-announces-new-data-to-be-presented-at-2023-digestive-disease-week-showcasing-the-potential-of-its-blood-based-technology-to-detect-colorectal-cancer\/","title":{"rendered":"Guardant Health announces new data to be presented at 2023 Digestive Disease Week showcasing the potential of its blood-based technology to detect colorectal cancer"},"content":{"rendered":"
\n

\nThe data from the pivotal ECLIPSE Study accepted as a late-breaking abstract highlights the performance of the Shield<\/i>\u2122<\/i> blood test in detecting colorectal cancer in asymptomatic patients<\/i><\/p>\n

<\/a><\/p>\n

PALO ALTO, Calif.–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, is pleased to announce that it will present data from two studies highlighting the performance of its blood-based screening technology to detect early-stage colorectal cancer (CRC), including the acceptance of the ECLIPSE study as a late-breaking abstract, at Digestive Disease Week (DDW) taking place in Chicago, Illinois on May 6-9, 2023.<\/p>\n

\n\u201cDespite multiple screening modalities for colorectal cancer, screening rates remain stubbornly low leaving many cancers undetected. A blood test that can accurately detect CRC represents a significant opportunity to overcome some of the known challenges with patient adherence,\u201d said AmirAli Talasaz, Guardant Health co-CEO. \u201cWe are thrilled that DDW has accepted the ECLIPSE study, one of the largest studies of its kind, as a late-breaking abstract, and we look forward to sharing this new data with the healthcare community at this year\u2019s meeting.\u201d<\/p>\n

\n\u201cThe need for a convenient, less invasive way to screen for CRC is great, and an accurate blood test can play a critical role in improving screening rates, especially for those reluctant to get screened,\u201d said Daniel Chung, MD, gastroenterologist at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School. \u201cI look forward to presenting at DDW and sharing new data from the ECLIPSE Study on the performance and potential of the Shield blood test to help improve adherence to screening.”<\/p>\n

\nThe ECLIPSE Study late-breaking abstract and one additional abstract highlighting the potential of Guardant Health\u2019s blood-based screening technology are now available online through the DDW meeting planner<\/a>. The presentation on Tuesday, May 9 will include further data and trial design analysis beyond what is included in the online abstract. Details of the presentations are as follows:<\/p>\n\n\n\n\n\n\n
\n

\nAbstract<\/b><\/p>\n<\/td>\n

\n

\nSession<\/b><\/p>\n<\/td>\n

\n

\nTitle<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\nTuesday, May 9 | 9:00-9:15am CT<\/i><\/p>\n<\/td>\n<\/tr>\n

\n

\n#3910067<\/p>\n<\/td>\n

\n

\nDDW Clinical Late Breaking Session #5095<\/p>\n<\/td>\n

\n

\nClinical Validation of a Cell-Free DNA Blood-Based Test for Colorectal Cancer in an Average Risk Population<\/p>\n

\nPresenter: Daniel Chung, MD, gastroenterologist at Massachusetts General Hospital and professor of medicine at Harvard Medical School<\/p>\n<\/td>\n<\/tr>\n

\n

\nTuesday, May 9 | 12:30-1:30pm CT<\/i><\/p>\n<\/td>\n<\/tr>\n

\n

\n#Tu1132<\/p>\n<\/td>\n

\n

\nPoster Session #9050<\/p>\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nAssessment of an Early Version Blood Based Multimodal cfDNA Assay for the Detection of Colorectal Cancer Incorporating the Assessment of ctDNA Genomic Alterations and Epigenomic Modifications<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nAbout Digestive Disease Week\u00ae<\/b><\/p>\n

\nDigestive Disease Week\u00ae (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW is an in-person and online meeting from May 6-9, 2023. The meeting showcases more than 3,100 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org<\/a>.<\/p>\n

\nAbout Guardant Health<\/b><\/p>\n

\nGuardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360\u00ae, Guardant360 CDx, Guardant360 TissueNext\u2122, Guardant360 Response\u2122, and GuardantINFINITY\u2122 tests for advanced-stage cancer patients, and Guardant Reveal\u2122 for early-stage cancer patients. The Guardant Health screening portfolio, including the commercially launched Shield\u2122 test, aims to address the needs of individuals eligible for cancer screening. For more information, visit guardanthealth.com<\/a> and follow the company on LinkedIn<\/a> and Twitter<\/a>.<\/p>\n

\nGuardant Health Forward-Looking Statement<\/b><\/p>\n

\nThis press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health\u2019s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health\u2019s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operation\u201d and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2022, and any current and periodic reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health\u2019s views as of any date subsequent to the date of this press release.<\/p>\n

Contacts<\/b> <\/p>\n

\nGuardant Health Contacts<\/b>
Investor Contact:<\/b>
Alex Kleban
\n
investors@guardanthealth.com<\/a>
+1 657-254-5417
\n<\/p>\n

\nMedia Contact:<\/b>
Breen Weir
\n
press@guardanthealth.com<\/a>
+1 843-384-0095<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

The data from the pivotal ECLIPSE Study accepted as a late-breaking abstract highlights the performance of the Shield\u2122 blood test in detecting colorectal cancer in asymptomatic patients PALO ALTO, Calif.–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, is pleased to announce that it will present data from two studies highlighting the performance … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-56089","6":"format-standard","7":"category-industry"},"yoast_head":"\nGuardant Health announces new data to be presented at 2023 Digestive Disease Week showcasing the potential of its blood-based technology to detect colorectal cancer - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/guardant-health-announces-new-data-to-be-presented-at-2023-digestive-disease-week-showcasing-the-potential-of-its-blood-based-technology-to-detect-colorectal-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Guardant Health announces new data to be presented at 2023 Digestive Disease Week showcasing the potential of its blood-based technology to detect colorectal cancer - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"The data from the pivotal ECLIPSE Study accepted as a late-breaking abstract highlights the performance of the Shield\u2122 blood test in detecting colorectal cancer in asymptomatic patients PALO ALTO, Calif.–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, is pleased to announce that it will present data from two studies highlighting the performance ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/guardant-health-announces-new-data-to-be-presented-at-2023-digestive-disease-week-showcasing-the-potential-of-its-blood-based-technology-to-detect-colorectal-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-21T13:03:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230421005227\/en\/1330243\/21\/GuardantHealthLogo_TM_RGB-2C.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guardant-health-announces-new-data-to-be-presented-at-2023-digestive-disease-week-showcasing-the-potential-of-its-blood-based-technology-to-detect-colorectal-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guardant-health-announces-new-data-to-be-presented-at-2023-digestive-disease-week-showcasing-the-potential-of-its-blood-based-technology-to-detect-colorectal-cancer\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Guardant Health announces new data to be presented at 2023 Digestive Disease Week showcasing the potential of its blood-based technology to detect colorectal cancer\",\"datePublished\":\"2023-04-21T13:03:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guardant-health-announces-new-data-to-be-presented-at-2023-digestive-disease-week-showcasing-the-potential-of-its-blood-based-technology-to-detect-colorectal-cancer\\\/\"},\"wordCount\":921,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guardant-health-announces-new-data-to-be-presented-at-2023-digestive-disease-week-showcasing-the-potential-of-its-blood-based-technology-to-detect-colorectal-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230421005227\\\/en\\\/1330243\\\/21\\\/GuardantHealthLogo_TM_RGB-2C.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guardant-health-announces-new-data-to-be-presented-at-2023-digestive-disease-week-showcasing-the-potential-of-its-blood-based-technology-to-detect-colorectal-cancer\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guardant-health-announces-new-data-to-be-presented-at-2023-digestive-disease-week-showcasing-the-potential-of-its-blood-based-technology-to-detect-colorectal-cancer\\\/\",\"name\":\"Guardant Health announces new data to be presented at 2023 Digestive Disease Week showcasing the potential of its blood-based technology to detect colorectal cancer - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guardant-health-announces-new-data-to-be-presented-at-2023-digestive-disease-week-showcasing-the-potential-of-its-blood-based-technology-to-detect-colorectal-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guardant-health-announces-new-data-to-be-presented-at-2023-digestive-disease-week-showcasing-the-potential-of-its-blood-based-technology-to-detect-colorectal-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230421005227\\\/en\\\/1330243\\\/21\\\/GuardantHealthLogo_TM_RGB-2C.jpg\",\"datePublished\":\"2023-04-21T13:03:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guardant-health-announces-new-data-to-be-presented-at-2023-digestive-disease-week-showcasing-the-potential-of-its-blood-based-technology-to-detect-colorectal-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guardant-health-announces-new-data-to-be-presented-at-2023-digestive-disease-week-showcasing-the-potential-of-its-blood-based-technology-to-detect-colorectal-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guardant-health-announces-new-data-to-be-presented-at-2023-digestive-disease-week-showcasing-the-potential-of-its-blood-based-technology-to-detect-colorectal-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230421005227\\\/en\\\/1330243\\\/21\\\/GuardantHealthLogo_TM_RGB-2C.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230421005227\\\/en\\\/1330243\\\/21\\\/GuardantHealthLogo_TM_RGB-2C.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guardant-health-announces-new-data-to-be-presented-at-2023-digestive-disease-week-showcasing-the-potential-of-its-blood-based-technology-to-detect-colorectal-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Guardant Health announces new data to be presented at 2023 Digestive Disease Week showcasing the potential of its blood-based technology to detect colorectal cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Guardant Health announces new data to be presented at 2023 Digestive Disease Week showcasing the potential of its blood-based technology to detect colorectal cancer - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/guardant-health-announces-new-data-to-be-presented-at-2023-digestive-disease-week-showcasing-the-potential-of-its-blood-based-technology-to-detect-colorectal-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Guardant Health announces new data to be presented at 2023 Digestive Disease Week showcasing the potential of its blood-based technology to detect colorectal cancer - Pharma Trend","og_description":"The data from the pivotal ECLIPSE Study accepted as a late-breaking abstract highlights the performance of the Shield\u2122 blood test in detecting colorectal cancer in asymptomatic patients PALO ALTO, Calif.–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, is pleased to announce that it will present data from two studies highlighting the performance ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/guardant-health-announces-new-data-to-be-presented-at-2023-digestive-disease-week-showcasing-the-potential-of-its-blood-based-technology-to-detect-colorectal-cancer\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-21T13:03:31+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230421005227\/en\/1330243\/21\/GuardantHealthLogo_TM_RGB-2C.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/guardant-health-announces-new-data-to-be-presented-at-2023-digestive-disease-week-showcasing-the-potential-of-its-blood-based-technology-to-detect-colorectal-cancer\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/guardant-health-announces-new-data-to-be-presented-at-2023-digestive-disease-week-showcasing-the-potential-of-its-blood-based-technology-to-detect-colorectal-cancer\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Guardant Health announces new data to be presented at 2023 Digestive Disease Week showcasing the potential of its blood-based technology to detect colorectal cancer","datePublished":"2023-04-21T13:03:31+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/guardant-health-announces-new-data-to-be-presented-at-2023-digestive-disease-week-showcasing-the-potential-of-its-blood-based-technology-to-detect-colorectal-cancer\/"},"wordCount":921,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/guardant-health-announces-new-data-to-be-presented-at-2023-digestive-disease-week-showcasing-the-potential-of-its-blood-based-technology-to-detect-colorectal-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230421005227\/en\/1330243\/21\/GuardantHealthLogo_TM_RGB-2C.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/guardant-health-announces-new-data-to-be-presented-at-2023-digestive-disease-week-showcasing-the-potential-of-its-blood-based-technology-to-detect-colorectal-cancer\/","url":"https:\/\/pharma-trend.com\/en\/guardant-health-announces-new-data-to-be-presented-at-2023-digestive-disease-week-showcasing-the-potential-of-its-blood-based-technology-to-detect-colorectal-cancer\/","name":"Guardant Health announces new data to be presented at 2023 Digestive Disease Week showcasing the potential of its blood-based technology to detect colorectal cancer - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/guardant-health-announces-new-data-to-be-presented-at-2023-digestive-disease-week-showcasing-the-potential-of-its-blood-based-technology-to-detect-colorectal-cancer\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/guardant-health-announces-new-data-to-be-presented-at-2023-digestive-disease-week-showcasing-the-potential-of-its-blood-based-technology-to-detect-colorectal-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230421005227\/en\/1330243\/21\/GuardantHealthLogo_TM_RGB-2C.jpg","datePublished":"2023-04-21T13:03:31+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/guardant-health-announces-new-data-to-be-presented-at-2023-digestive-disease-week-showcasing-the-potential-of-its-blood-based-technology-to-detect-colorectal-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/guardant-health-announces-new-data-to-be-presented-at-2023-digestive-disease-week-showcasing-the-potential-of-its-blood-based-technology-to-detect-colorectal-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/guardant-health-announces-new-data-to-be-presented-at-2023-digestive-disease-week-showcasing-the-potential-of-its-blood-based-technology-to-detect-colorectal-cancer\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230421005227\/en\/1330243\/21\/GuardantHealthLogo_TM_RGB-2C.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230421005227\/en\/1330243\/21\/GuardantHealthLogo_TM_RGB-2C.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/guardant-health-announces-new-data-to-be-presented-at-2023-digestive-disease-week-showcasing-the-potential-of-its-blood-based-technology-to-detect-colorectal-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Guardant Health announces new data to be presented at 2023 Digestive Disease Week showcasing the potential of its blood-based technology to detect colorectal cancer"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56089","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=56089"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56089\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=56089"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=56089"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=56089"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}